Drug Trial Radar · NCT05366621
Post-fracture Medication and Mortality
Last checked: Nov 19, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216,155
Actual
Start
Nov 1, 2020
Primary completion
Sep 30, 2021
Study completion Oct 31, 2021
Sponsor
- Lead sponsor
- National Cheng-Kung University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 9, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. The investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. The investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.
Conditions
- Osteoporosis
- Osteoporosis Fracture
- Drug Therapy
- Mortality
- Adherence, Medication
Interventions
Anti-osteoporosis medicationsDrug
Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of deaths with and without anti-osteoporotic therapy after hip fracture surgeryTime frame: 12 years
- Number of deaths with or without anti-osteoporosis therapy after hip or vertebral fracture surgery among older adultsTime frame: 12 years
- Number of deaths with and without bisphosphonates after hip or spine fracture surgeryTime frame: 12 years
- Number of deaths with different types of anti-osteoporosis treatments after post-fractureTime frame: 12 years
- Number of deaths in five leading causes of death with and without anti-osteoporosis treatment after post-fractureTime frame: 12 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Family Medicine, National Cheng Kung Univ Hosp
Tainan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.